National Pension Service Sells 23,911 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

National Pension Service trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Rating) by 13.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 156,987 shares of the biopharmaceutical company’s stock after selling 23,911 shares during the quarter. National Pension Service owned 0.13% of Alnylam Pharmaceuticals worth $32,872,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Nuveen Asset Management LLC grew its holdings in Alnylam Pharmaceuticals by 5,486.1% during the 3rd quarter. Nuveen Asset Management LLC now owns 16,593,268 shares of the biopharmaceutical company’s stock worth $3,321,309,000 after acquiring an additional 16,296,223 shares during the last quarter. Vanguard Group Inc. grew its holdings in Alnylam Pharmaceuticals by 1.2% during the 1st quarter. Vanguard Group Inc. now owns 10,829,144 shares of the biopharmaceutical company’s stock worth $1,768,291,000 after acquiring an additional 126,373 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Alnylam Pharmaceuticals by 3.0% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 6,997,082 shares of the biopharmaceutical company’s stock worth $1,020,524,000 after acquiring an additional 202,916 shares during the last quarter. State Street Corp grew its holdings in Alnylam Pharmaceuticals by 2.7% during the 2nd quarter. State Street Corp now owns 2,988,859 shares of the biopharmaceutical company’s stock worth $435,925,000 after acquiring an additional 79,369 shares during the last quarter. Finally, Invesco Ltd. grew its holdings in Alnylam Pharmaceuticals by 8.8% during the 1st quarter. Invesco Ltd. now owns 968,755 shares of the biopharmaceutical company’s stock worth $158,187,000 after acquiring an additional 78,665 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. EF Hutton Acquisition Co. I started coverage on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 21st. They set a “buy” rating and a $304.00 target price on the stock. Canaccord Genuity Group dropped their price target on shares of Alnylam Pharmaceuticals from $310.00 to $291.00 and set a “buy” rating on the stock in a research report on Friday, February 24th. JPMorgan Chase & Co. dropped their price target on shares of Alnylam Pharmaceuticals from $200.00 to $196.00 and set a “neutral” rating on the stock in a research report on Friday, March 3rd. StockNews.com started coverage on shares of Alnylam Pharmaceuticals in a research report on Thursday. They issued a “hold” rating on the stock. Finally, Morgan Stanley dropped their price target on shares of Alnylam Pharmaceuticals from $210.00 to $205.00 and set an “equal weight” rating on the stock in a research report on Friday, February 24th. Seven analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $244.26.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $189.66 on Friday. The company has a debt-to-equity ratio of 3.85, a quick ratio of 3.34 and a current ratio of 3.51. The company’s fifty day moving average price is $214.61 and its two-hundred day moving average price is $213.51. Alnylam Pharmaceuticals, Inc. has a 1-year low of $117.58 and a 1-year high of $242.97.

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Rating) last posted its earnings results on Thursday, February 23rd. The biopharmaceutical company reported ($1.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.13) by $0.45. Alnylam Pharmaceuticals had a negative net margin of 109.04% and a negative return on equity of 1,287.80%. The firm had revenue of $335.04 million during the quarter, compared to analyst estimates of $312.45 million. During the same quarter in the prior year, the business posted ($2.16) EPS. The business’s revenue was up 29.6% compared to the same quarter last year. As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -6.93 earnings per share for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 18,072 shares of the company’s stock in a transaction on Friday, March 3rd. The shares were sold at an average price of $200.00, for a total value of $3,614,400.00. Following the completion of the sale, the chief marketing officer now owns 4,345 shares in the company, valued at approximately $869,000. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, EVP Indrani Lall Franchini sold 1,675 shares of the stock in a transaction dated Thursday, February 2nd. The shares were sold at an average price of $226.01, for a total transaction of $378,566.75. Following the completion of the transaction, the executive vice president now owns 3,500 shares in the company, valued at $791,035. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 18,072 shares of the stock in a transaction dated Friday, March 3rd. The shares were sold at an average price of $200.00, for a total transaction of $3,614,400.00. Following the transaction, the chief marketing officer now owns 4,345 shares of the company’s stock, valued at approximately $869,000. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Alnylam Pharmaceuticals Profile

(Get Rating)

Alnylam Pharmaceuticals, Inc is a global commercial-stage biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Its products include ONPATTRO, GIVLAARI, and OXLUMO. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.